AR-SA">B-cell depletion and recovery after treatment with the anti-CD20 monoclonal antibody rituximab in patients with posttransplant lymphoproliferative disorders (PT-LPD).

被引：0
|
作者：
Grefer, J
Oertel, SH
Hummel, M
Serke, S
Reinke, P
Jonas, S
Anagnostopoulos, I
Arnold, R
Dörken, B
Riess, H
机构：
[1] Humboldt Univ, Klinikum Rudolf Virchow, Charite, Berlin, Germany
[2] Deutsches Herzzentrum, Berlin, Germany
[3] Free Univ Berlin, D-1000 Berlin, Germany
来源：
BLOOD | 2001年 / 98卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4693
引用
收藏
页码：242B / 242B
页数：1
相关论文
共 50 条
  • [21] Development of a new fully human anti-CD20 monoclonal antibody for the treatment of B-cell malignancies
    Bornstein, Gadi Gazit
    Queva, Christophe
    Tabrizi, Mohammad
    van Abbema, Anne
    Chavez, Carlos
    Wang, Ping
    Foord, Orit
    Ahluwalia, Kiran
    Laing, Naomi
    Raja, Sandhya
    Wen, Shenghua
    Green, Larry L.
    Yang, Xiaodong
    Webster, Carl
    Stewart, Ross
    Blakey, David
    INVESTIGATIONAL NEW DRUGS, 2010, 28 (05) : 561 - 574
  • [22] CD20-negative relapse of cutaneous B-cell lymphoma after anti-CD20 monoclonal antibody therapy
    Massengale, WT
    McBurney, E
    Gurtler, J
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2002, 46 (03) : 441 - 443
  • [23] Ibrutinib Exposure and B-Cell Depletion Induced By Anti-CD20 Monoclonal Antibodies Rituximab and Obinutuzumab: Is There a Rationale for Combination Studies?
    Ysebaert, Loic
    Klein, Christian
    Quillet-Mary, Anne
    BLOOD, 2014, 124 (21)
  • [24] The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura
    Cooper, N
    Stasi, R
    Cunningham-Rundles, SS
    Feuerstein, MA
    Leonard, JP
    Amadori, S
    Bussel, JB
    BRITISH JOURNAL OF HAEMATOLOGY, 2004, 125 (02) : 232 - 239
  • [25] Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: A retrospective analysis on 32 patients
    Milpied, N
    Vasseur, B
    Parquet, N
    Garnier, JL
    Antoine, C
    Quartier, P
    Carret, AS
    Bouscary, D
    Faye, A
    Bourbigot, B
    Reguerre, Y
    Stoppa, AM
    Bourquard, P
    de Ligny, BH
    Dubief, F
    Mathieu-Boue, A
    Leblond, V
    ANNALS OF ONCOLOGY, 2000, 11 : 113 - 116
  • [26] Clinical impact of B-cell depletion with the anti-CD20 antibody rituximab in chronic fatigue syndrome: a preliminary case series
    Øystein Fluge
    Olav Mella
    BMC Neurology, 9
  • [27] Clinical impact of B-cell depletion with the anti-CD20 antibody rituximab in chronic fatigue syndrome: a preliminary case series
    Fluge, Oystein
    Mella, Olav
    BMC NEUROLOGY, 2009, 9
  • [28] Quality of life in patients with B-cell lymphoma during maintenance therapy with the Anti-CD20 antibody rituximab
    Witzens-Harig, Mathias
    Heiss, Christiane
    Benner, Axel
    Hensel, Manfred
    Neben, Kai
    Dreger, Peter
    Kraemer, Alwin
    Ho, Anthony D.
    BLOOD, 2007, 110 (11) : 189B - 189B
  • [29] Rituximab (anti-CD20 monoclonal antibody) immunotherapy in patients with B-cell non-Hodgkin's lymphoma:: highly effective treatment of residual disease
    Papajík, T
    Szotkowski, T
    Raida, L
    Hubáek, J
    Faber, E
    Hlusí, A
    Vondráková, J
    Pikalová, Z
    Jedliková, K
    Jarosová, M
    Indrák, K
    LEUKEMIA, 2001, 15 (03) : 510 - 510
  • [30] Intralesional therapy with anti-CD20 monoclonal antibody rituximab: local and systemic efficacy in primary cutaneous B-cell lymphoma
    Roguedas, AM
    Watier, H
    Paintaud, G
    de Muret, A
    Vaillant, L
    Machet, L
    BRITISH JOURNAL OF DERMATOLOGY, 2005, 152 (03) : 541 - 544
12345